Hemispherx Biopharma, Inc (HEB)
0.68USD
4:00pm EST
$0.00 (+0.00%)
$0.68
$0.69
$0.69
$0.67
1,154,152
3,285,744
$4.54
$0.26
HEB
About
Overall
| Beta: | 0.78 |
| Market Cap (Mil.): | $90.25 |
| Shares Outstanding (Mil.): | 132.72 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| HEB | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 6.43 | 3.76 |
| EPS (TTM): | 22.95 | -- | -- |
| ROI: | -30.92 | 5.95 | 2.30 |
| ROE: | -30.92 | 8.98 | 2.82 |
FACTBOX-Drugs in development to prevent, treat influenza
LOS ANGELES, May 7 (Reuters) - Given the heightened awareness of influenza and the threat of a global pandemic, it is not surprising that the pharmaceutical industry is dedicating significant research efforts to the development of new therapeutics.
Hemispherx to terminate Ampligen marketing license to Esteve
Dec 10 (Reuters) - Hemispherx Biopharma Inc said it plans to terminate the license agreement with Esteveto to market Ampligen, a drug to treat chronic fatigue syndrome, citing non-performance by Esteve of certain contractually required clinical trials. Esteve has sought arbitration and damages, but Hemispherx said the claim lacks merit and that it plans to counterclaim, seeking damages.
Hemispherx says board member resigned due to differences
Nov 29 (Reuters) - Hemispherx Biopharma Inc said Steven Spence resigned from the board, effective Nov. 20, due to differences in perspective on corporate strategy with a majority of the directors.
TABLE-Hemispherx Biopharma Q2 net loss narrows
HEMISPHERX BIOPHARMA INC. (in $) Latest Yr-ago qtr Loss/shr (diluted) 0.05 0.08 Net loss (million) 3.9 5.1 Total revenue (thousands) 234 247 Reuters Estimates: Loss/shr $0.07 (one analyst) (Reporting by Bhaswati Mukhopadhyay in Bangalore)
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $17.88 | +0.04 |
| GlaxoSmithKline plc (GSK.L) | £1,218.50 | -0.50 |
| Wyeth (WYE.N) | -- | -- |
| Wyeth (WYE_p.N) | -- | -- |
| Merck & Co., Inc. (MRK.N) | $36.47 | -0.12 |
| Novartis AG (NOVN.VX) | CHF56.80 | -0.40 |
| Gilead Sciences, Inc. (GILD.OQ) | $46.33 | +0.24 |
| Schering-Plough Corporation (SGP.N) | -- | -- |
| AVI BioPharma, Inc. (AVII.OQ) | $1.45 | -0.04 |
| Genta Incorporated (GETA.OB) | $0.10 | -0.00 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
